Stephanie Pilkington Partner and Board Member

Stephanie Pilkington
  • Personal profile
  • News and publications

Personal profile


Specialisms include: Molecular biology; biochemistry; drug screening; personalised and stratified medicine; diagnostic and prognostic markers for cancer and other diseases; therapeutic strategies; microarray and nucleic acid technology; medical devices. Filing and prosecution strategy; life cycle management; SPCs (supplementary protection certificates); oppositions; freedom to operate; due diligence investigations; CIPA Life Sciences Committee member and active member of subcommittees, for example relating to SPCs.

MA (Cantab; Part II Biochemistry), PhD (University of Cambridge; Molecular Biology)

Fellow of the Chartered Institute of Patent Attorneys, European Patent Attorney, CIPA Life Sciences Committee member 

Research/Industry experience: PhD and post-doc at MRC Laboratory of Molecular Biology, Cambridge, UK: 1987-1994 Fisons Pharmaceuticals, then Astra AB 1994-1997.

Stephanie read natural sciences (biochemistry) at Trinity College, Cambridge, before completing a PhD in molecular biology at the Medical Research Council's Laboratory of Molecular Biology (LMB) in Cambridge. After continuing her research at the LMB and serving as a Research Fellow at Lucy Cavendish College, Cambridge, she worked for Fisons Pharmaceuticals, then Astra AB, as a research biochemist. Stephanie joined Potter Clarkson in 1997 and became a Partner in 2004. In 2014, she was appointed a member of the Board of Management. Her experience is wide-ranging and includes extensive experience in advising SMEs and academic technology transfer departments.

Stephanie has extensive experience of both prosecution and oppositions at the EPO and regularly advises on filing and prosecution strategy as well as oppositions and due diligence investigations. She has also advised on SPC strategy in relation to small molecules and biologics, and has prosecuted SPC applications in the UK and elsewhere. Stephanie is an active contributor to SPC discussions and policy submissions through the CIPA Life Sciences Committee and has been named as one of the 2017 WIPR Leaders. 

Examples of clients:

  • Imperial Innovations Ltd
  • LGC Group
  • AGA Medical Corporation
  • InterMune, Inc (with US counsel Marshall, Gerstein & Borun LLP)

 
Experience:

  • Drafting and prosecution work for Imperial Innovations Ltd over a wide range of biomedical projects 
  • Opposition and appeal work, both defending and opposing, for AGA Medical Corporation, relating to medical devices
  • Prosecution and opposition work for InterMune, Inc, working with US counsel Marshall, Gerstein & Borun LLP